Thyroid News

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant.

Adults receiving teprotumumab for the treatment of thyroid eye disease experience a similar number of hearing-related adverse events as those not treated with teprotumumab, according to new data.

Adults with subclinical hypothyroidism may have a lower risk for major adverse cardiovascular events if they receive levothyroxine therapy compared with no treatment, according to a study published in Thyroid.

Women with subclinical hypothyroidism during the first half of pregnancy are more likely to develop overt hypothyroidism 5 years after delivery than women with hypothyroxinemia, according to a study published in Thyroid.

A parathyroid hormone prodrug developed to treat hypoparathyroidism received FDA approval, according to an industry press release.

Polygenic score is a stronger predictor for thyroid-stimulating hormone levels than free thyroxine and other factors, and could be used to develop individual TSH reference ranges for adults, according to findings published in Thyroid.

The presence of thyroid autoantibodies may be detected as early as age 10 months for children, and those positive for both thyroid peroxidase and thyroglobulin autoantibodies have a higher risk for thyroid disease, according to study data.

Women with primary hyperparathyroidism have similar pregnancy rates, maternal outcomes and neonatal outcomes as those without primary hyperparathyroidism, according to study data.